诺和龙治疗2型糖尿病合并动脉粥样硬化患者的疗效观察  

Study on clinical effect of Novonorm on treating type 2 diabetic patients with atherosclerosis

作　　者：陈寒蓓[1] 柳怿[2] 李晓永[1] 

机构地区：[1]上海交通大学医学院附属新华医院内分泌科,200092 [2]上海交通大学医学院附属新华医院超声诊断科,200092

出　　处：《中国综合临床》2010年第11期1187-1189,共3页Clinical Medicine of China

摘　　要：目的 观察诺和龙治疗2型糖尿病合并动脉粥样硬化患者的临床疗效.方法 将65例2型糖尿病合并动脉粥样硬化患者随机分为诺和龙组（36例）和优哒灵组（29例）,诺和龙组患者降糖药均为诺和龙治疗,优哒灵组均为优哒灵治疗,观察疗程12个月,监测治疗前后的血糖含量和颈动脉内膜中层厚度.结果 诺和龙组能有效降低餐后血糖（1.99±1.06）mmol/L,优哒灵降低餐后血糖（0.99±0.54）mmol/L,2组比较差异有统计学意义（P＜0.05）.诺和龙组治疗后颈动脉内膜中层厚度比治疗前减少[（1.02±0.08）、（1.11±0.07）mm]（P＜0.05）,优哒灵组治疗后颈动脉内膜中层厚度与治疗前比较无差异[（1.07±0.06）、（1.10±0.08）mm]（P＞0.05）.结论 诺和龙是一种安全、有效的降糖药物,适于2型糖尿病合并动脉粥样硬化患者的治疗.Objective To assess the clinical effect of Novonorm on treating type 2 diabetic patients with atherosclerosis. Methods Sixty-five patients of type 2 diabetes with atherosclerosis were randomly divided into 2 groups ：36 patients took Novonorm,and the other 29 individuals were treated with Glipizide. The blood glucose and CIMT were compared before and after treatment for 12 months. Results The postprandial blood glucose decreased by（1.99 ± 1.06）mmol/L after the treatment of Novonorm,which was significantly higher than that of（0. 99 ±0. 54）mmol/L after the treatment of Glipizide（P 〈 0. 05）. CIMT significantly decreased from （1.11 ± 0. 07）mm before treatment to（1.02 ± 0. 08）mm after treatment in the Novonorm group（P 〈 0. 05）,whereas CIMT were similar between after and before treatment in the Glipizide group（1.07 ± 0. 06）mm vs.（1.10 ± 0. 08）mm（P 〉 0. 05）.Conclusions Novonorm is a kind of effective and safe regent,which can be used to treat type 2 diabetic patients with atherosclerosis.

关 键 词：诺和龙 2型糖尿病 动脉粥样硬化 

分 类 号：R587.1[医药卫生—内分泌]